Search
for
Sort by
Research 301–330 of 724
- Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease
- Skin Manifestations in Primary Immunodeficient Children
- Alopecia areata: a review on diagnosis, immunological etiopathogenesis and treatment options
- Ablative Fractional Resurfacing in Topical Drug Delivery: An Update and Outlook
- Alopecia areata update
- Psychocutaneous disease
- Acquired scalp alopecia. Part II: A review
- Skin disease in pregnancy
- Hypersensitivity Reactions to Anticoagulant Drugs
- Skin disorders in elderly subjects
- Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
- Newborn infant skin gene expression: Remarkable differences versus adults
- Adverse cutaneous reactions to chemotherapeutic agents and cytokine therapy
- Adverse Dermatologic Effects of Cardiovascular Drug Therapy: Part III
- Part I: Accuracy of Teledermatology in Inflammatory Dermatoses
- Psychoactive drugs and skin
- Drug eruptions in dermatology
- Update on the Treatment of Alopecia Areata
- Irreversible alopecia universalis during treatment with pegylated interferon-ribavirin for chronic hepatitis C virus infection: Case report and published work review
- The Role of Cytochrome P-450 in Dermatology
- Guidelines for the Management of Patients with Alopecia Areata in Korea: Part I Topical and Device-based Treatment
- Acneiform Rash Caused by an Unlikely Drug: Topiramate
- Significance of iron status in hair loss in women
- Potential Use of Spin Traps to Control ROS in Antipollution Cosmetics—A Review
- Dermoscopy: distinguishing malignant tumors from benign
- Off-label use of biologics and janus kinase (JAK) inhibitors for scarring alopecias: a narrative review
- Aberrant inflammasome activation as a driving force of human autoimmune skin disease
- 277 An open label pilot clinical trial of the JAK inhibitor tofacitinib for alopecia areata
- Cytokines
- Management of Toxicities of Targeted Therapies